Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

NCT03588078 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome With Gene Mutation
Acute Myeloid Leukemia With Gene Mutations
Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia

Interventions

DRUG: APR-246
DRUG: Azacitidine

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]